A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 1, 2012, Pages 29-39

  Leifke, E ^a   Naik, H ^a   Wu, J ^a   Viswanathan, P ^a   DeManno, D ^a   Kipnes, M ^b   Vakilynejad, M ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

^b DGD Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; G PROTEIN COUPLED RECEPTOR 40; PLACEBO; TAK 875; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FLATULENCE; HEADACHE; HEMATOMA; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NECK PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VESSEL PUNCTURE SITE HEMATOMA;

ADMINISTRATION, ORAL; BENZOFURANS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; RECEPTORS, G-PROTEIN-COUPLED; SULFONES; TREATMENT OUTCOME;

EID: 84862589520     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.43     Document Type: Article

References (21)

1. Itoh, Y. et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422, 173-176 (2003).
2. Briscoe, C.P. et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 278, 11303-11311 (2003).
3. Kotarsky, K., Nilsson, N.E., Flodgren, E., Owman, C. & Olde, B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 301, 406-410 (2003).
4. Nagasumi, K. et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58, 1067-1076 (2009).
5. Itoh, Y. & Hinuma, S. GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. Hepatol. Res. 33, 171-173 (2005).
6. Sasaki, S. et al. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. J. Med. Chem. 54, 1365-1378 (2011).
7. Takeuchi, K., Tsujihata, Y., Ito, R., Suzuki, M., Harada, A. & Hazama, M. A selective GPR40 agonist, TAK-875, stimulates glucose-dependent insulin secretion without beta cell toxicity and decreases glycosylated hemoglobin levels in diabetic rats. Diabetologia. 53, S353 (Abstract) (2010).
8. Naik, H.et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double blind, placebo controlled single oral dose-rising study in healthy volunteers. J. Clin. Pharmacol. (2011); e-pub ahead of print 24 May 2011.
9. Matsuno, K., Hirayama, M., Araki, T., Dote, N., Kondo, T. & Nakamura, K. Pharmacokinetics, safety and tolerability of single and multiple doses of TAK-875, a novel GPR40 agonist, in Japanese healthy male subjects. Diabetes. 59, A193 (Abstract) (2010).
10. Burant, C. et al. TAK-875, a G protein-coupled receptor 40 agonist, for the treatment of type 2 diabetes mellitus: a phase ii, randomized, double-blind, placebo- and active-controlled study. Lancet 379, 1403-1411 (2012).
11. Soldatos, G. & Cooper, M.E. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res. Clin. Pract. 82 (suppl. 1), S75-S79 (2008).
12. Nathan, D.M. et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193-203 (2009).
13. Ripsin, C.M., Kang, H. & Urban, R.J. Management of blood glucose in type 2 diabetes mellitus. Am. Fam. Physician 79, 29-36 (2009).
14. Yashiro, H., Tsujihata, Y., Takeuchi, K., Hazama, M., Johnson, P.R. & Rorsman, P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J. Pharmacol. Exp. Ther. 340, 483-489 (2012).
15. Edfalk, S., Steneberg, P. & Edlund, H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57, 2280-2287 (2008).
16. Lebovitz, H.E. Treating hyperglycemia in type 2 diabetes: new goals and strategies. Cleve. Clin. J. Med. 69, 809-820 (2002).
17. Zammitt, N.N. & Frier, B.M. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28, 2948-2961 (2005).
18. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
19. Graveling, A.J. & Frier, B.M. Does hypoglycaemia cause cardiovascular events? Br. J. Diabetes. Vasc. Dis. 10, 5-13 (2010).
20. Zoungas, S. et al.; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med. 363, 1410-1418 (2010).
21. Tsujihata, Y. et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J. Pharmacol. Exp. Ther. 339, 228-237 (2011).